Remus Pharmaceuticals seeks shareholder approval via postal ballot for a material related party transaction between EBFL and Rise Pharma LLC, aggregating up to ₹100 crore for FY25-26, with e-voting from 15 November to 15 December 2025 and results by 17 December 2025.